Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis

PHASE2RecruitingINTERVENTIONAL

Enrollment

160

Participants

Timeline

Start Date

February 26, 2024

Primary Completion Date

April 28, 2026

Study Completion Date

August 28, 2026

Conditions

Psoriatic Arthritis

Interventions

DRUG

HS-10374

Administered orally QD for 16 weeks

DRUG

HS-10374-matched placebo tablets

Administered orally QD for 16 weeks

DRUG

Tofacitinib 5Mg Tab,Oral

Administered orally BID for 16 weeks

Trial Locations (1)

RECRUITING

Huashan Hospital affiliated to Fudan University, Shanghai

All Listed Sponsors

lead

Hansoh BioMedical R&D Company

INDUSTRY

NCT06176508 - Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis | Biotech Hunter | Biotech Hunter